Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

How a Ketogenic Diet Affects Hormones and Metabolism in Women (SHEKAN)

12 de noviembre de 2026 actualizado por: Madison Kackley, Ohio State University

Strategic Hormonal Evaluation in Keto-Adaptation

This study is looking at how a ketogenic diet (a way of eating that is high in fat and very low in carbohydrates) affects hormones, metabolism, and body composition in healthy women who have regular menstrual cycles. While ketogenic diets have become popular and have been studied in men and in people with certain health conditions, much less is known about how this way of eating affects the hormones and cycles of healthy, premenopausal women.

Researchers believe that a ketogenic diet may cause measurable changes in reproductive hormones (such as estrogen and progesterone), metabolic markers (like ketone and cholesterol levels), and body composition (such as body fat and lean muscle mass) across the menstrual cycle. The study will also explore whether the diet affects mood, sleep, and overall well-being.

Participants will follow a ketogenic diet for 12 weeks, roughly covering three menstrual cycles. During the first month, they will receive help with meal planning and food, and for the remaining weeks they will follow the diet on their own with continued support from a dietitian. Throughout the study, participants will check in weekly for blood draws, body composition scans, and a resting metabolism test, and will use at-home tools such as a smart ring and daily finger-stick tests to track their ketone levels and hormone patterns. Participants will also complete surveys about their mood, sleep, and general well-being.

By studying these changes closely, the research team hopes to better understand how a ketogenic diet affects women's health and hormones, which could help guide future dietary recommendations designed specifically for women.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

etogenic diets induce a metabolic shift from glucose to fat as the primary energy substrate, resulting in nutritional ketosis and associated changes in insulin sensitivity, lipid profiles, and body composition. While ketogenic diets have been studied extensively in the context of epilepsy, obesity, type 2 diabetes, and neurodegenerative disease, most existing research either underrepresents women or fails to account for hormonal fluctuations across the menstrual cycle. Preliminary evidence suggests that sex hormones and substrate metabolism differ meaningfully between men and women in their response to dietary interventions, yet these differences remain poorly characterized during ketogenic adaptation, particularly in healthy, regularly menstruating women.

This pilot study is designed to characterize the physiological, hormonal, metabolic, and behavioral adaptations that occur during a 12-week, well-formulated ketogenic diet in healthy, premenopausal women, capturing data across approximately three consecutive menstrual cycles. The diet is structured in two phases: an initial 4-week period with controlled feeding support (grocery provision or meal delivery services matched to individual caloric needs), followed by 8 weeks of self-guided dietary adherence supported by ongoing dietitian consultation and educational materials. Dietary adherence and ketosis status (target: ≥0.5 mmol/L blood BHB) are monitored daily via at-home fingerstick testing.

Participants attend weekly in-person study visits for the duration of the 12-week intervention, during which fasting venous blood is drawn to assess reproductive hormone levels, resting metabolic rate is measured via indirect calorimetry, and body composition is tracked using bioelectrical impedance (InBody). Full-body DXA scans, which provide a more precise measure of fat mass, lean mass, and visceral adiposity, are performed only at baseline and at the final Week 16 visit, in order to limit participants' cumulative radiation exposure. Menstrual cycle phase and ovulatory status are tracked continuously using a wearable basal body temperature ring and urine-based hormone test strips, allowing the research team to align hormonal blood draws with specific points in each participant's cycle. Validated PROMIS instruments are used to assess mood, sleep quality, anxiety, depression, and cognitive function at scheduled intervals throughout the study.

As a pilot study, SHEKAN is designed primarily to assess feasibility and estimate effect sizes to inform the design of future, larger-scale investigations, rather than to test a specific hypothesis with adequate statistical power to detect small between-group differences. Findings are intended to help characterize sex-specific responses to ketogenic diets and inform future research and clinical guidance regarding women's metabolic and reproductive health during dietary intervention.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • Physical Activity and Educational Services Building
        • Contacto:
          • Program Manager Department of Human Sciences - Kinesiology
          • Número de teléfono: 6142470287
          • Correo electrónico: roe.236@osu.edu
        • Investigador principal:
          • Madison Kackley, PhD, Kinesiology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 40 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Healthy Women aged 18-40
  • Self-reported, 27-32 day menstrual cycles
  • Must have access to a smartphone, tablet or computer to access the diet survey and resources
  • Must be willing to self-report menstrual cycles

Exclusion Criteria:

  • History of reproductive disorders
  • Pregnancy or lactation during the study period
  • Recurring disordered eating behaviors or other food security concerns
  • Suffered a lower body injury in the last 6 months
  • Other major health concerns

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Ketogenic Diet Intervention Group

Healthy, premenopausal women (ages 18-40) with regular menstrual cycles will follow a 12-week well-formulated ketogenic diet designed to maintain nutritional ketosis (≥0.5 mmol/L BHB). During the first 4 weeks, participants receive controlled feeding support (grocery provision or meal delivery services). Weeks 5-12 transition to a self-guided ketogenic diet with continued dietitian support and educational resources. Participants undergo weekly in-person study visits (blood draws, resting metabolic rate testing, body composition scans, and validated surveys) plus daily at-home monitoring (fingerstick ketone/glucose testing, nightly wearable ring, and urine ovulation tracking) across approximately 16 weeks total, including baseline and final follow-up visits.

A high-fat, low-carbohydrate, moderate-protein diet intended to induce and maintain nutritional ketosis over 12 weeks, with an initial 4-week period of controlled feeding support followed by 8 weeks of self-guided adherence with dietitian consultation and educational materials.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Ovulatory Status
Periodo de tiempo: Baseline to 12 weeks

To evaluate whether ketogenic dietary intervention or exogenous ketone supplementation restores ovulatory function in women with Polycystic Ovary Syndrome (PCOS). Ovulatory status will be assessed using a combination of validated measures, including basal body temperature monitoring via BBT, urinary luteinizing hormone (LH) surge detection using ovulation predictor kits, and serum progesterone levels. Participants will be classified as ovulatory or anovulatory based on hormonal and temperature cycle confirmation.

Baseline to 12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Serum Progesterone Concentration (ng/mL)
Periodo de tiempo: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum progesterone will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Estradiol Concentration (pg/mL)
Periodo de tiempo: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum estradiol will be analyzed using commercially available immunoassay kits (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Luteinizing Hormone Concentration (mIU/mL)
Periodo de tiempo: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum luteinizing hormone (LH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Follicle Stimulating Hormone Concentrations (mIU/mL)
Periodo de tiempo: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum follicle-stimulating hormone (FSH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Daily Fasting BHB (mmol/L)
Periodo de tiempo: Baseline to 12 weeks (Daily)

To assess changes in metabolic parameters including fasting β-hydroxybutyrate (BHB). Capillary ketones will be measured daily using KetoMojo handheld monitors.

Baseline to 12 weeks (Daily)
Change in Daily Fasting Glucose (mg/dL)
Periodo de tiempo: Baseline to 12 weeks (Daily)

To assess changes in metabolic parameters including fasting glucose. Capillary glucose will be measured daily using KetoMojo handheld monitors.

Baseline to 12 weeks (Daily)
Change in Serum Insulin Concentration (µIU/mL)
Periodo de tiempo: Baseline to 12 weeks

To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting insulin levels. Serum insulin will be measured at laboratory visits via immunoassay (Quest Diagnostics or validated ELISA). Mean change from baseline will be compared across groups.

Baseline to 12 weeks
Change in Serum Total Cholesterol Concentration (mg/dL)
Periodo de tiempo: Baseline to 12 weeks

To assess changes in fasting serum total cholesterol in response to ketogenic diet and exogenous ketone supplementation. Blood samples will be collected biweekly and analyzed using standard clinical chemistry methods (Quest Diagnostics). Mean change from baseline to 12 weeks will be reported.

Baseline to 12 weeks
Change in Serum Triglyceride Concentration (mg/dL)
Periodo de tiempo: Baseline to 12 weeks

To determine the effect of ketogenic diet and exogenous ketone supplementation on fasting triglyceride concentrations. Serum triglycerides will be measured via standard lipid panel. Mean change from baseline to 12 weeks will be compared across groups.

Baseline to 12 weeks
Change in Serum LDL Cholesterol Concentration (mg/dL)
Periodo de tiempo: Baseline to 12 weeks

To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting low-density lipoprotein (LDL) cholesterol. Serum LDL will be measured via standard lipid panel (Quest Diagnostics). Mean change from baseline to post-intervention will be reported.

Baseline to 12 weeks
Change in Serum HDL Cholesterol Concentration (mg/dL)
Periodo de tiempo: Baseline to 12 weeks

To evaluate changes in fasting high-density lipoprotein (HDL) cholesterol following ketogenic diet or exogenous ketone supplementation. Serum HDL will be analyzed by clinical chemistry methods. Mean change from baseline to 12 weeks will be reported.

Baseline to 12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de febrero de 2026

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

2 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY20250337

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified datasets (no direct identifiers; no genetic/genomic data, as none will be generated for this study)

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .